康希诺2025年净利2787.27万元，同比扭亏

Core Viewpoint - The company 康希诺 (CanSino) reported a significant turnaround in its financial performance for the year 2025, achieving a notable increase in revenue and a return to profitability after a previous loss [1] Financial Performance - The company achieved an operating revenue of 1.068 billion yuan, representing a year-on-year growth of 26.18% [1] - The net profit attributable to the company was 27.87 million yuan, a substantial improvement from a loss of 379 million yuan in the same period last year [1] Strategic Initiatives - 康希诺 emphasized its commitment to innovation and commercialization as key components of its development strategy [1] - The company reported continuous growth in revenue from its first quadrivalent meningococcal vaccine, 曼海欣 (Manhaixin) [1] - Cost reduction and efficiency improvement measures were effectively implemented, leading to better expense management [1] Operational Efficiency - The company optimized its production and sales coordination, which contributed to an increase in gross profit margin [1] - Overall, 康希诺 demonstrated a significant enhancement in its profitability during the reporting period [1]